ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

DT-01-01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY

10.1016/j.jalz.2019.08.004 ◽

2019 ◽

Vol 15 ◽

pp. P1484-P1484 ◽

Cited By ~ 2

Author(s):

Jose Luis Molinuevo ◽

Akihiko Koyama ◽

Shobha Dhadda ◽

Michael C. Irizarry ◽

Chad J. Swanson ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Phase 2 Study ◽

Biomarker Analysis ◽

Early Alzheimer’S Disease ◽

Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer’s Disease: A Randomized Phase 2 Study

Journal of Alzheimer s Disease ◽

10.3233/jad-150414 ◽

2015 ◽

Vol 48 (2) ◽

pp. 473-481 ◽

Cited By ~ 12

Author(s):

Serge Gauthier ◽

Susan Rountree ◽

Barbara Finn ◽

Barbra LaPlante ◽

Eckard Weber ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Acetylcholine Release ◽

Phase 2 ◽

Release Agent ◽

Phase 2 Study ◽

P1-392: DRUG DEVELOPMENT FOR AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE (AD): STUDY DESIGN AND OUTCOME MEASURES IN PHASE 2 STUDY OF SCYLLO-INOSITOL (ELND005 STUDY AG201)

10.1016/j.jalz.2014.05.634 ◽

2014 ◽

Vol 10 ◽

pp. P458-P458 ◽

Cited By ~ 1

Author(s):

Susan R. Abushakra ◽

Patrick Kesslak ◽

Matthias Kurth ◽

Frank Fan ◽

Menghis Bairu ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Drug Development ◽

Outcome Measures ◽

Study Design ◽

Phase 2 ◽

P2-067: Modifications in Albumin Molecular Profile in a Phase 2 Study Based on Therapeutic Plasma Exchange and 5% Albumin Replacement in Alzheimer's Disease

10.1016/j.jalz.2016.06.1272 ◽

2016 ◽

Vol 12 ◽

pp. P633-P634

Author(s):

Montserrat Costa ◽

Ana María Ortiz ◽

Raquel Horrillo ◽

Alba Pérez ◽

Mercè Boada ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Plasma Exchange ◽

Therapeutic Plasma Exchange ◽

Molecular Profile ◽

Phase 2 ◽

FTS3-01-03: PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT

10.1016/j.jalz.2019.06.4620 ◽

2019 ◽

Vol 15 ◽

pp. P873-P873

Author(s):

Robert A. Stern ◽

Alette M. Wessels ◽

Katherine J. Selzler ◽

Scott W. Andersen ◽

Jamie Mullen ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Early Alzheimer’S Disease ◽

The Effects of ELND005 (Scyllo-Inositol) on Emergence of Neuropsychiatric Symptoms (NPS) in Mild/Moderate Alzheimer's Disease: Results from a 78-Week Phase 2 Study (P04.215)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.p04.215 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. P04.215-P04.215 ◽

Cited By ~ 1

Author(s):

P. Tariot ◽

C. Lyketsos ◽

G. Crans ◽

J. Cedarbaum ◽

C. Hernandez ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Neuropsychiatric Symptoms ◽

Phase 2 ◽

P-015: A responder analysis of MPC-7869 (tarenflurbil), a selective Aβ42-lowering agent, in mild Alzheimer's disease (AD): Analysis from a phase 2 study of up to 24 months of treatment

10.1016/j.jalz.2007.04.231 ◽

2007 ◽

Vol 3 (3S_Part_1) ◽

pp. S99-S100 ◽

Cited By ~ 1

Author(s):

Kenton H. Zavitz ◽

Suzanne Hendrix ◽

Mark Laughlin ◽

Edward Swabb

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Responder Analysis ◽

P3-301: Dextromethorphan/quinidine (AVP-923) phase 2 study for treatment of agitation in Alzheimer's disease: Comparing the enrolled agitation sample with the international psychogeriatric association definition of agitation in cognitive disorders (NCT015

10.1016/j.jalz.2015.06.1675 ◽

2015 ◽

Vol 11 (7S_Part_16) ◽

pp. P751-P751

Author(s):

Jeffrey L. Cummings ◽

Constantine Lyketsos ◽

Elaine R. Peskind ◽

Anton P. Porsteinsson ◽

Jacobo E. Mintzer ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Disorders ◽

Phase 2 ◽

Phase 2 Study ◽

Definition Of

P4-389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE-2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD-TO-MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE

10.1016/j.jalz.2018.07.213 ◽

2006 ◽

Vol 14 (7S_Part_31) ◽

pp. P1623-P1623 ◽

Cited By ~ 5

Author(s):

Shau Yu Lynch ◽

June Kaplow ◽

Jim Zhao ◽

Shobha Dhadda ◽

Johan Luthman ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Phase 2 ◽

Moderate Dementia ◽

Bace Inhibitor ◽

ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY

10.1016/j.jalz.2019.06.075 ◽

2019 ◽

Vol 15 (7) ◽

pp. P251-P252

Author(s):

Hana Florian ◽

Steven E. Arnold ◽

Randall Bateman ◽

Joel B. Braunstein ◽

Kumar Budur ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Monoclonal Antibody ◽

Phase 2 ◽

Phase 2 Study ◽

Baseline Characteristics ◽

Early Alzheimer’S Disease